Results 271 to 280 of about 72,887 (326)

Der Poly(ADP)-Ribose-Polymerase-Inhibitor INO-1001reduziert den Reperfusionsschaden der Leber nachhämorrhagischem Schock und Reperfusion

, 2011
Stephan Quest
openalex   +2 more sources

Denosumab Regulates Titanium Particles‐Induced Macrophages Inflammation and Osteolysis by Targeting the ST18/PARP1 Interaction

Orthopaedic Surgery, Volume 18, Issue 2, Page 322-334, February 2026.
The schematic diagram of the role of Denosumab and ST18/PARP1 axis in the prevention of prosthesis‐related AL. Denosumab regulates TiPs‐induced macrophage activation and osteolysis through the NF‐κB pathway and M1 polarization, with ST18 acting as a key mediator.
Zhipeng Chen, Fan Yang, Yifan Yu, Junxi Chen, Jichao Ye, Yue Ding   +5 more
wiley   +1 more source

Epigenomics‐guided precision oncology: Chromatin variants in prostate tumor evolution

International Journal of Cancer, Volume 158, Issue 2, Page 314-332, 15 January 2026.
Abstract Prostate cancer is a common malignancy that in 5%–30% leads to treatment‐resistant and highly aggressive disease. Metastasis‐potential and treatment‐resistance is thought to rely on increased plasticity of the cancer cells—a mechanism whereby cancer cells alter their identity to adapt to changing environments or therapeutic pressures to create
Kira Furlano, Tina Keshavarzian, Nadine Biernath, Annika Fendler, Maria de Santis, Joachim Weischenfeldt, Mathieu Lupien   +6 more
wiley   +1 more source

Real-world data-based assessment of therapy-related myeloid neoplasms after poly(ADP-ribose) polymerase inhibitor treatment in ovarian cancer [PDF]

Ryosuke Uekusa, Akira Yokoi, Eri Watanabe, Mikako Inoue, Katsuhiko Mizuno, Kosuke Yoshida, Nobuhisa Yoshikawa, Kaoru Niimi, Shiro Suzuki, Hiroaki Kajiyama   +9 more
openalex   +1 more source

Efficacy of Poly(ADP-ribose) Polymerase Inhibitors by Individual Genes in Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer: A US Food and Drug Administration Pooled Analysis. [PDF]

J Clin Oncol
Fallah J, Xu J, Weinstock C, Gao X, Heiss BL, Maguire WF, Chang E, Agrawal S, Tang S, Amiri-Kordestani L, Pazdur R, Kluetz PG, Suzman DL.   +12 more
europepmc   +1 more source

12P A novel anti-TCR Vb targeted bispecific antibody in combination with a poly ADP ribose polymerase inhibitor (PARPi) enhances anti-tumor immune response in a prostate cancer model

Ginette S. Santiago-Sánchez, Francesca Rosato, Michael Padget, J Schlom, James L. Gulley, Andy Bayliffe, Zhen Su, Jacques Moisan, Madan Katragadda, James W. Hodge   +9 more
openalex   +1 more source

Development of substituted 6-[4-fluoro-3-(piperazin-1-ylcarbonyl)benzyl]-4,5-dimethylpyridazin-3(2H)-ones as potent poly(ADP–ribose) polymerase-1 (PARP-1) inhibitors active in BRCA deficient cells

, 2009
Federica Ferrigno, Danila Branca, Olaf Kinzel, Samuele Lillini, Laura Llauger Bufi, Edith Monteagudo, Ester Muraglia, Michael Rowley, Carsten Schultz‐Fademrecht, Carlo Toniatti, Caterina Torrisi, Philip Jones   +11 more
openalex   +1 more source

Design and synthesis of poly(ADP-ribose)polymerase-1 (PARP-1) inhibitors. Part 3: In vitro evaluation of 1,3,4,5-Tetrahydro-benzo[c][1,6]- and [c][1,7]-naphthyridin-6-ones

, 2003
Dana Ferraris, Rica Pargas Ficco, Thomas F. Pahutski, Susan Lautar, Shirley Huang, Jie Zhang, Vincent J. Kalish   +6 more
openalex   +1 more source

Selective small molecule PARG inhibitor causes replication fork stalling and cancer cell death [PDF]

, 2019
al., et, Ellenberger, Tom, Houl, Jerry H., Kim, In-Kwon, Stegeman, Roderick A.   +4 more
core   +1 more source

Significance of CA125 Monitoring during Maintenance Treatment with Poly(ADP-Ribose) Polymerase Inhibitor in Ovarian Cancer after First-Line Chemotherapy: Multicenter, Observational Study

Szymon Piątek, Anna Dańska-Bidzińska, Paweł Derlatka, Bartosz Szymanowski, Renata Duchnowska, Aleksandra Zielińska, Nadia Sawicka, Aleksander Gorzeń, Wojciech Michalski, Mariusz Bidziński   +9 more
openalex   +2 more sources